drugset / Trial / NCT01425359

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

NCT01425359 ↗

Phase 4 Completed 949 enrolled Gilead Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM), and whether ranolazine can reduce the frequency of angina (chest pain) attacks, compared to a placebo. Subjects will be asked to record their daily angina episodes in a diary at the end of each study day. Ranolazine is approved for the treatment of chronic angina, and is not approved for the treatment of T2DM.

Timeline

Start
2011-09
Primary completion
2012-10
Completion
2012-10

Outcome

Met primary endpoint

paper Weekly angina frequency was significantly lower with ranolazine versus placebo PMID 23500237 ↗

registry analysis (superiority or other test); Placebo vs Ranolazine; p = 0.008; Generalized linear model; NCT01425359 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 1000 mg —